Status:
COMPLETED
Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Hypertension
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study is designed as a mechanistic study to compare the effect of two different combinations of anti-hypertensive treatments (aliskiren and valsartan vs. telmisartan and ramipril) on the renin-an...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Males or females of non-childbearing potential, 18 to 65 years of age with moderate hypertension
- Patients who are eligible and able to participate in the study
- Exclusion criteria:
- Severe hypertension or secondary form of hypertension.
- Serum potassium \> 5.1 mEq/L (mmol/L)
- Heart failure
- Any history of hypertensive encephalopathy or cerebrovascular accident; any history of TIA, myocardial infarction, coronary bypass surgery or percutaneous coronary intervention
- Uncontrolled or life-threatening arrythmia
- Other protocol-defined inclusion/exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT00939588
Start Date
July 1 2009
Last Update
November 18 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Moscow, Russia